“FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth," says Jean-Luc Procaccini, CEO, molecular imaging and CT.
Members of the specialty should begin their next job with an exit strategy in mind or risk losing a hefty sum in the process, according to a new opinion piece.
Satoshi Minoshima, MD, PhD, first took on the title in November 2014 and will remain in a clinical role while IR specialist Chuck Ray, MD, PhD, takes over as interim chair.
Researchers with Northwestern University in Chicago detailed their novel system in an analysis published by the Journal of the American College of Radiology.
The boost comes after the Los Angeles-based imaging center chain recently closed a $259M public stock offering, with a sizable chunk earmarked for expansion initiatives.
Large language models could have feasibility in the future as clinical support tools that triage patients for imaging services—with additional updates and more training, of course.
“FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth," says Jean-Luc Procaccini, CEO, molecular imaging and CT.
Jaime Warren, EdD, FACC, vice president of care transformation at MedAxiom, an ACC company, explains what is needed to address staffing shortages created by a 94% increase in cardiac CT volumes over the past 5 years.
